Abstract
Aims
Cardiac resynchronization therapy (CRT) improves functional status, induces reverse left ventricular remodelling, and reduces hospitalization and mortality in patients with symptomatic heart failure, left ventricular systolic dysfunction, and QRS prolongation. However, the impact of iron deficiency on CRT response remains largely unclear. The purpose of the study was to assess the effect of functional and absolute iron deficiency on reverse cardiac remodelling, clinical response, and outcome after CRT implantation.
Methods and results
The relation of iron deficiency and cardiac resynchronization therapy response (RIDE‐CRT) study is a prospective observational study. We enrolled 77 consecutive CRT recipients (mean age 71.3 ± 10.2 years) with short‐term follow‐up of 3.3 ± 1.9 months and long‐term follow‐up of 13.0 ± 3.2 months. Primary endpoints were reverse cardiac remodelling on echocardiography and clinical CRT response, assessed by change in New York Heart Association classification. Echocardiographic CRT response was defined as relative improvement of left ventricular ejection fraction ≥ 20% or left ventricular global longitudinal strain ≥ 20%. Secondary endpoints were hospitalization for heart failure and all‐cause mortality (mean follow‐up of 29.0 ± 8.4 months). At multivariate analysis, iron deficiency was identified as independent predictor of echocardiographic (hazard ratio 4.97; 95% confidence interval 1.15–21.51; P = 0.03) and clinical non‐response to CRT (hazard ratio 4.79; 95% confidence interval 1.30–17.72, P = 0.02). We found a significant linear‐by‐linear association between CRT response and type of iron deficiency (P = 0.004 for left ventricular ejection fraction improvement, P = 0.02 for left ventricular global longitudinal strain improvement, and P = 0.003 for New York Heart Association response). Iron deficiency was also significantly associated with an increase in all‐cause mortality (P = 0.045) but not with heart failure hospitalization.
Conclusions
Iron deficiency is a negative predictor of effective CRT therapy as assessed by reverse cardiac remodelling and clinical response. Assessment of iron substitution might be a relevant treatment target to increase CRT response and outcome in chronic heart failure patients.
Keywords: Iron deficiency, Cardiac resynchronization therapy, Heart failure
1. Introduction
Cardiac resynchronization therapy (CRT) is a proven and well‐established method for the management of symptomatic heart failure (HF) in patients with reduced left ventricular (LV) systolic function and prolongation of the QRS interval.1 Numerous large randomized multicenter trials have demonstrated that CRT alleviates electromechanical dyssynchrony in patients with HF, thereby reducing LV size and mitral regurgitation, improving LV ejection fraction, quality of life, exercise capacity, and functional status [improvements of ≥1 New York Heart Association (NYHA) class].2, 3, 4 In addition, CRT is associated with a significant reduction in hospitalization for HF and all‐cause mortality.5, 6, 7
However, a variable proportion of system recipients, depending on the definition and criteria applied, do not benefit from CRT.8, 9 The prevalence of clinical non‐responders, defined as patients with no improvement in NYHA functional class, is nearly 30% while that of echocardiographic non‐responders, identified by an increase in LV end‐systolic volume < 10%, is reported around 45%.10 However, non‐response to CRT is multifactorial and includes pre‐implant, peri‐implant, and post‐implant factors.11 Possible reasons include inadequate selection of candidates, suboptimal lead position, irreversible end‐stage disease, extensive scar burden, and inadequate device programming (atrioventricular delay and interventricular delay). Thus, non‐response to CRT therapy remains the Achilles' heel of CRT therapy, associated with considerable financial and medical challenges.
Iron deficiency (ID) is known to be a frequent and important co‐morbidity in patients with heart failure with reduced ejection fraction with a prevalence of up to 50%.12 In addition, ID constitutes the most frequent cause of anaemia in these patients. However, even more important, ID occurs in around 45% of non‐anaemic patients with systolic HF.13 ID can be either absolute, when total body iron is decreased, or functional, when iron content is normal or increased, but does not meet the needs of the target tissue due to maldistribution. ID, with or without concomitant anaemia, has been shown to worsen symptoms and impair exercise capacity and quality of life and increases mortality and hospitalization in patients with HF.14, 15, 16, 17 Moreover, absolute ID was found to be associated with an increased risk of early readmission after an episode of acute HF.18
Beside its role in oxygen transport and storage, iron is a key component of diverse enzymes involved in cellular respiration, oxidative phosphorylation, citric acid cycle, and reactive oxygen species (ROS) scavenging enzymes.19 Numerous studies demonstrated that intravenous iron supplementation improves exercise capacity, functional status, and quality of life in iron deficient patients with chronic HF.20, 21, 22, 23 However, data on impact of ID on response to CRT therapy are limited.24, 25 Thus, the aim of the present study was to assess the impact of functional and absolute ID at CRT implantation on reverse cardiac remodelling, clinical response, and outcome of CRT.
2. Methods
2.1. Study design
The relation of iron deficiency and cardiac resynchronization therapy response (RIDE‐CRT) study is a prospective observational trial evaluating the impact of functional and absolute ID with and without concomitant anaemia on echocardiographic and clinical CRT response. Primary endpoints were clinical response (defined as improvement in NYHA functional class ≥ 1) and reverse cardiac remodelling [defined as relative improvement of LV ejection fraction ≥ 20% or relative increase of LV global longitudinal strain (LV GLS) ≥20%] on echocardiography. Secondary endpoints were all‐cause mortality and hospitalization for HF. Hospitalization for HF was defined as admission primarily for its treatment. A patient admitted for this reason had to show signs and symptoms of worsening HF and require treatment with intravenous diuretics. Evidence of worsening of HF had to include at least one of the following points: increasing exertional dyspnoea, orthopnoea, pulmonary oedema, increasing peripheral oedema, deterioration in renal function, and radiological signs of acute decompensated HF.
The study protocol was approved by the human ethics committee of the Charité—Universitaetsmedizin Berlin (ethic application number: EA2/107/13) and is in accordance with the Declaration of Helsinki. All patients provided written informed consent. The study was registered on German Clinical Trials Register (DRKS00015304).
2.2. Study population
Between November 2012 and January 2016, a total of 103 patients were prospectively enrolled in the RIDE‐CRT study at our institution (Department of Internal Medicine and Cardiology, University Hospital). All patients received a CRT device in accordance with current guidelines.1
Eligible subjects for implantation of a biventricular device with or without a defibrillator function were (i) patients who had chronic HF of NYHA Class II, III, or IV, an LV ejection fraction ≤35%, a prolonged QRS duration (≥120 ms), and adequate pharmacotherapy and (ii) pacemaker patients with a right ventricular (RV) pacing‐induced cardiomyopathy (defined as ≥10% decrease in LVEF, with resultant LVEF < 50%).26 Anaemia was defined according to the definitions of the World Health Organization with haemoglobin levels less than 13 g/dL in men and less than 12 g/dL in women.27 ID was diagnosed as serum ferritin level less than 100 μg/L (absolute ID), or serum ferritin level 100–299 μg/L and transferrin saturation less than 20% (functional ID).18, 28 Patients who received red blood cell transfusion or iron substitution during the follow‐up period and patients with inadequate biventricular pacing were excluded from the analysis.
2.3. Patient evaluation and follow‐up
Baseline characteristics included age, gender, body mass index, aetiology of HF, type of CRT (CRT‐D or CRT‐P), electrocardiogram (ECG) analysis, relevant co‐morbidities, concomitant medication, and laboratory values. In addition, NYHA functional class, echocardiographic parameters [LV end‐systolic volume (LVESV), LV end‐diastolic volume (LVEDV), LV end‐systolic diameter, LV end‐systolic volume index, LV end‐diastolic volume index, LVEF, LV GLS, degree of mitral valve, and tricuspid valve regurgitation], and parameters of iron metabolism (haemoglobin, iron, ferritin, and transferrin saturation) were measured at baseline and at follow‐up. Response to CRT was assessed at short‐term (3.3 ± 1.9 months) and long‐term (13.0 ± 3.2 months) follow‐up, always with clinical evaluation and device testing. Follow‐up for the secondary endpoint mortality was 29.0 ± 8.4 months.
2.4. Left ventricular assessment by echocardiography
Echocardiographic parameters were obtained according to a pre‐specified protocol in a central echocardiography laboratory at our institution using a Vivid 7 or E9 (GE Healthcare) ultrasound system. Images were analysed offline with commercially available software (Echo‐Pac) by European Association of Cardiovascular Imaging certified observers blinded to the clinical and functional outcome of the patients in the echocardiography core lab (Echo CoreLab, Charité Berlin). Conventional LV measurements were performed as recommended by the European Association of Cardiovascular Imaging.29 LVESV and LVEDV as well as LVEF were analysed using the biplane Simpson's method. LV global longitudinal systolic strain was assessed by 2D speckle tracking, averaging the value of the longitudinal systolic strain peak from all segments of the LV in the apical 4‐chamber, 2‐chamber, and long‐axis views in accordance with the recommendations for LV strain measurements of European Association of Cardiovascular Imaging.30 Only patients with echocardiographic high image quality for LV GLS (n = 77) were included in the data analysis. All reported measurements were calculated as the average of three measurements and performed at conditions of respiratory and haemodynamic stability.
2.5. Cardiac resynchronization therapy device implantation
Cardiac resynchronization therapy (CRT) devices with or without defibrillator function from Biotronik, Medtronic, Boston Scientific, and St. Jude Medical (now Abbot) were used. Device implantations were carried out in a hybrid catheter laboratory (room air class 1B) using a monoplane heart catheter system. All patients received an atrial lead, and the LV lead was implanted transvenously in all cases. RV pacing was performed either from the apex or from the mid‐septum. The LV lead was placed in a posterolateral or lateral vein. A quadripolar LV lead was implanted in 53.2% of the patients from our study cohort. All CRT devices were programmed to biventricular pacing (no ‘LV only’ programming).
2.6. Definition of cardiac resynchronization therapy response
Echocardiographic CRT response was defined as relative improvement of the LVEF ≥ 20% or LV GLS ≥ 20%.31 Patients with an LVEF ≥ 50% were classified as super‐responder.32 Clinical response was defined as improvement ≥1 NYHA functional class.
2.7. Statistical analysis
Quantitative measurements are presented as mean values with standard deviation. Ordinal and nominal values are shown as absolute and relative frequencies. Spearman's correlation coefficient was used for bivariate correlation analysis. Differences in metric values between independent binary groups were evaluated with Mann–Whitney U test, while for independent ternary groups, Kruskal–Wallis test was used. The Wilcoxon test was used to compare baseline values with follow‐up values. Comparison between nominal values was performed with Pearson's chi‐square test. Evaluation of linear trends of nominal with ordinal or both ordinal values was performed with Mantel–Haenszel linear‐by‐linear association. Adjustment for potential confounders and the identification of independent possible predictors for non‐response to CRT were performed using binary logistic regression analyses. For this matter, parameters significantly associated with non‐response in univariate analysis were taken into consideration, followed by forward and backward selection. Cox regression analysis was used to calculate unadjusted and adjusted hazard ratios. Kaplan–Meier survival analysis and log‐rank test expressed the chronological sequence of occurring events (hospitalization and death) in a survival curve and disparity among different groups. Two‐sided P‐values ≤0.05 were considered significant, and no Bonferroni correction was performed due to the exploratory character of this study. SPSS Statistics Version 24 (IBM Corporation) was used for each statistical analysis.
3. Results
3.1. Baseline clinical and echocardiographic parameters
Between November 2012 and January 2016, a total of 103 patients were enrolled in the RIDE‐CRT study. Echocardiography with high image quality for LV GLS analysis was available in only 77 patients (mean age 71.3 ± 10.2, 68.8% male). The patients' baseline clinical characteristics are summarized in Table 1. Causes of HF were ischaemic cardiomyopathy (54.5%), idiopathic dilated cardiomyopathy (32.5%), RV pacing‐induced cardiomyopathy (6.5%), valvular cardiomyopathy (5.2%), and hypertrophic cardiomyopathy (1.3%). In total, 42 patients (54.5%) received a de novo CRT implantation, whereas 35 patients (45.5%) were upgraded to CRT from a pacemaker or an implantable cardioverter defibrillator. Of note, 31.2% of the patients had a history of atrial fibrillation, and among these, 41.7% had paroxysmal and 58.3% persisting/permanent atrial fibrillation. The RV lead was placed in the RV apex in 44 (57.1%) patients, and at the RV septum in 33 (42.9%) patients. LV lead position was posterior/posterolateral midventricular in 53 (68.8%), posterior/posterolateral basal in 16 (20.8%), lateral midventricular in 3 (3.9%), and lateral basal in 5 (6.5%) of the patients. Iron deficient and non‐iron deficient patients had similar baseline characteristics with respect to age, gender, NYHA functional class, body mass index and prevalence of diabetes mellitus, and arterial hypertension. However, patients with ID were more likely to have coronary artery disease, chronic renal failure with a glomerular filtration rate < 60 mL/min*1.73 m2 and more often received loop diuretics and antiplatelet therapy, whereas the prevalence of dilated cardiomyopathy and use of aldosterone antagonist was more frequent in patients with no ID. Anaemia according to the definition of the World Health Organization was statistically more frequent in patients with ID than in those with normal iron metabolism. The patient baseline echocardiographic and ECG parameters are shown in Table 2. The mean value of LVEF at baseline was 24.0 ± 9.7% with an LVESV of 122.1 ± 44.8 mL, an LVEDV of 158.3 ± 52.7 mL, an LV end‐systolic volume index of 64.2 ± 26.5 mL, and an LV GLS of 6.0 ± 2.1%. No significant differences in the collected baseline echocardiographic and ECG parameters were observed between patients with normal iron metabolism compared with those with ID (Table 2).
Table 1.
Baseline demographics and clinical characteristics of the study population
| Baseline characteristics | Total population (n = 77) | No iron deficiency (n = 34) | Functional iron deficiency (n = 19) | Absolute iron deficiency (n = 24) | Iron deficiency (n = 43) | P ID vs. no ID |
|---|---|---|---|---|---|---|
| Age (years) ± SD | 71.3 ± 10.2 | 68.6 ± 11.8 | 71.6 ± 10.1 | 74.8 ± 6.6 | 73.4 ± 8.4 | 0.078 |
| Body mass index (kg/m2 ± SD) | 28.5 ± 4.9 | 28.2 ± 4.8 | 29.4 ± 5.0 | 28.1 ± 5.1 | 28.7 ± 5.0 | 0.735 |
| Male sex | 53 (68.8%) | 24 (70.6%) | 11 (57.9%) | 18 (75.0%) | 29 (67.4%) | 0.767 |
| NYHA functional class | ||||||
| I | 0 | 0 | 0 | 0 | 0 | — |
| II | 14 (18.2%) | 7 (20.6%) | 5 (26.3%) | 2 (8.3%) | 7 (16.3%) | 0.626 |
| III | 55 (71.4%) | 25 (73.5%) | 11 (57.9%) | 19 (79.2%) | 30 (69.8%) | 0.717 |
| IV | 8 (10.4%) | 2 (5.9%) | 3 (15.8%) | 3 (12.5%) | 6 (14.0%) | — |
| Type of implanted device | ||||||
| CRT‐D | 69 (89.6%) | 31 (94.2%) | 17 (89.5%) | 21 (87.5%) | 38 (88.4%) | 0.689 |
| CRT‐P | 8 (10.4%) | 3 (8.8%) | 2 (10.5%) | 3 (12.5%) | 5 (11.6%) | 0.689 |
| Co‐morbidities | ||||||
| Ischaemic cardiomyopathy | 42 (54.5%) | 13 (38.2%) | 11 (57.9%) | 18 (75.0%) | 29 (67.4%) | 0.011 |
| Dilated cardiomyopathy | 25 (32.5%) | 17 (50.0%) | 6 (31.6%) | 2 (8.3%) | 8 (18.6%) | 0.003 |
| Valvular cardiomyopathy | 4 (5.2%) | 1 (2.9%) | 2 (10.5%) | 1 (4.2%) | 3 (7.0%) | — |
| Hypertrophic cardiomyopathy | 1 (1.3%) | 1 (2.9%) | 0 | 0 | 0 | — |
| Pacing‐induced cardiomyopathy | 5 (6.5%) | 2 (5.9%) | 0 | 3 (12.5%) | 3 (7.0%) | — |
| Myocardial infarction within previous 3 months | 4 (5.2%) | 1 (2.9%) | 1 (5.3%) | 2 (8.3%) | 3 (7.0%) | — |
| PCI within previous 3 months | 7 (9.1%) | 3 (8.8%) | 2 (10.5%) | 2 (8.3%) | 4 (9.3%) | — |
| CABG within previous 3 months | 0 (0.0%) | 0 | 0 | 0 | 0 | — |
| Atrial fibrillation | 24 (31.2%) | 9 (26.5%) | 5 (26.3%) | 10 (41.7%) | 15 (34.9%) | 0.429 |
| Paroxysmal | 10 (13.0%) | 2 (5.9%) | 3 (15.8%) | 5 (20.8%) | 8 (18.6%) | — |
| Persistent/permanent | 14 (18.2%) | 7 (20.6%) | 2 (10.5%) | 5 (20.8%) | 7 (16.3%) | 0.626 |
| AV block | ||||||
| I | 17 (22.1%) | 8 (23.5%) | 5 (13.9%) | 4 (16.7%) | 9 (20.9%) | 0.785 |
| II | 2 (2.6%) | 2 (5.9%) | 0 | 0 | 0 | — |
| III | 10 (13.0%) | 5 (14.7%) | 2 (10.5%) | 3 (12.5%) | 5 (11.6%) | 0.690 |
| AV node ablation | ||||||
| Before CRT | 1 (1.3%) | 0 | 0 | 1 (4.2%) | 1 (2.3%) | — |
| After CRT | 0 (0.0%) | 0 | 0 | 0 | 0 | — |
| Anaemia | 34 (44.2%) | 9 (26.5%) | 11 (57.9%) | 14 (58.3%) | 25 (58.1%) | 0.006 |
| Diabetes mellitus type 1 and 2 | 27 (35.1%) | 8 (23.5%) | 9 (47.4%) | 10 (41.7%) | 19 (44.2%) | 0.059 |
| Arterial hypertension | 59 (76.6%) | 25 (73.5%) | 14 (73.7%) | 20 (83.3%) | 34 (79.1%) | 0.568 |
| Hyperlipoproteinemia | 47 (61.0%) | 18 (52.9%) | 13 (68.4%) | 16 (66.7%) | 29 (67.4%) | 0.195 |
| Chronic renal failure (GFR < 60 mL/min) | 44 (57.1%) | 13 (38.2%) | 14 (73.7%) | 17 (70.8%) | 31 (72.1%) | 0.003 |
| Chronic obstructive pulmonary disease | 15 (19.5%) | 5 (14.7%) | 3 (15.8%) | 7 (29.2%) | 10 (23.3%) | 0.347 |
| Stroke/TIA | 11 (14.3%) | 4 (11.8%) | 2 (10.5%) | 5 (20.8%) | 7 (16.3%) | — |
| Laboratory values | ||||||
| Haemoglobin (g/dL ± SD) | 12.5 ± 2.0 | 13.1 ± 2.0 | 12.1 ± 1.7 | 12.1 ± 2.2 | 12.1 ± 2.0 | 0.031 |
| Creatinine (mg/dL ± SD) | 1.4 ± 0.5 | 1.3 ± 0.6 | 1.5 ± 0.6 | 1.4 ± 0.4 | 1.5 ± 0.5 | 0.024 |
| Glomerular filtration rate (mL/min*1.73m2 ± SD) | 54.6 ± 20.5 | 62.6 ± 21.8 | 46.9 ± 19.2 | 49.5 ± 15.5 | 48.3 ± 17.1 | 0.002 |
| Medication | ||||||
| ACE inhibitor or ARB | 68 (88.3%) | 30 (88.2%) | 17 (89.5%) | 21 (87.5%) | 38 (88.4%) | 0.985 |
| Beta‐blocker | 72 (93.5%) | 32 (94.1%) | 19 (100.0%) | 21 (87.5%) | 40 (93.0%) | 0.847 |
| Amiodarone | 18 (23.4%) | 7 (20.6%) | 4 (21.0%) | 7 (29.2%) | 11 (25.6%) | 0.607 |
| Digitalis glycoside | 8 (10.4%) | 3 (8.8%) | 2 (10.5%) | 3 (12.5%) | 5 (11.6%) | — |
| Loop diuretics | 69 (89.6%) | 26 (76.5%) | 19 (100.0%) | 24 (100.0%) | 43 (100.0%) | 0.001 |
| Aldosterone antagonist | 47 (61.0%) | 26 (76.5%) | 9 (47.4%) | 12 (50.0%) | 21 (48.8%) | 0.014 |
| Anticoagulant therapy | 32 (41.6%) | 12 (35.3%) | 9 (47.4%) | 11 (45.8%) | 20 (46.5%) | 0.321 |
| Antiplatelet therapy | 45 (58.4%) | 15 (44.1%) | 11 (57.9%) | 19 (79.2%) | 30 (69.8%) | 0.023 |
| Lipid lowering therapy | 54 (70.1%) | 21 (61.8%) | 15 (79.0%) | 18 (75.0%) | 33 (76.7%) | 0.154 |
ABG, coronary artery bypass grafting; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; AV, atrioventricular; CRT, cardiac resynchronization therapy; GFR, glomerular filtration rate; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SD, standard deviation. Data are presented as mean ± SD or as n (%).
Table 2.
Baseline electrocardiographic and echocardiographic parameters
| Electrocardiographic and echocardiographic parameters at baseline | Total population (n = 77) | No ID (n = 34) | Functional ID (n = 19) | Absolute ID (n = 24) | ID (n = 43) | P (ID vs. no ID) |
|---|---|---|---|---|---|---|
| ECG | ||||||
| Heart rate (b.p.m. ± SD) | 72.5 ± 18.3 | 72.9 ± 16.7 | 73.7 ± 23.3 | 71.1 ± 16.5 | 72.2 ± 19.6 | 0.361 |
| PQ interval (ms ± SD) | 193.8 ± 64.0 | 202.43 ± 76.3 | 185.6 ± 52.8 | 189.7 ± 57.0 | 187.8 ± 54.3 | 0.809 |
| QRS duration (ms ± SD) | 162.2 ± 24.4 | 165.7 ± 20.3 | 155.2 ± 25.5 | 162.7 ± 28.6 | 159.4 ± 27.2 | 0.088 |
| Left bundle branch block | 31 (40.3%) | 14 (41.2%) | 9 (47.4%) | 8 (33.3%) | 17 (39.5%) | 0.884 |
| Left anterior hemi‐block | 13 (16.9%) | 6 (17.7%) | 4 (21.1%) | 3 (12.5%) | 7 (16.3%) | 0.874 |
| Right bundle branch block | 10 (13.0%) | 4 (11.8%) | 4 (21.1%) | 2 (8.3%) | 6 (14.0%) | — |
| Intraventricular conduction defect | 9(11.7%) | 3 (8.8%) | 2 (10.5%) | 4 (16.7%) | 6 (14.0%) | — |
| Right ventricular pacing | 5 (6.5%) | 2 (5.9%) | 0 | 3 (12.5%) | 3 (7.0%) | — |
| Echocardiography | ||||||
| LVEDV (mL) | 158.3 ± 52.7 | 164.3 ± 52.8 | 156.7 ± 51.9 | 151.1 ± 54.5 | 153.6 ± 52.8 | 0.397 |
| LVEDVi (mL/m2) | 82.9 ± 31.4 | 88.2 ± 36.6 | 80.2 ± 25.2 | 77.7 ± 27.9 | 78.8 ± 26.4 | 0.361 |
| LVESV (mL) | 122.1 ± 44.8 | 126.0 ± 43.9 | 124.5 ± 43.2 | 114.8 ± 48.1 | 119.1 ± 45.7 | 0.518 |
| LVESVi (mL/m2) | 64.2 ± 26.5 | 67.9 ± 30.0 | 63.7 ± 20.5 | 59.3 ± 25.6 | 61.2 ± 23.3 | 0.515 |
| LVEF (%) | 24.0 ± 9.7 | 23.4 ± 8.9 | 23.2 ± 8.4 | 25.3 ± 11.7 | 24.4 ± 10.3 | 0.711 |
| LV GLS (%) | 6.0 ± 2.1 | 5.7 ± 1.9 | 6.2 ± 1.8 | 6.4 ± 2.6 | 6.3 ± 2.3 | 0.204 |
| MR grade | ||||||
| I | 40 (52.0%) | 18 (53.0%) | 12 (63.2%) | 10 (41.7%) | 22 (51.2%) | 0.877 |
| II | 9 (11.7%) | 4 (9.3%) | 1 (5.3%) | 4 (16.7%) | 5 (11.6%) | — |
| III | 0 | 0 | 0 | 0 | 0 | — |
| TR grade | ||||||
| I | 39 (50.6%) | 20 (58.8%) | 9 (47.4%) | 10 (41.7%) | 19 (44.2%) | 0.186 |
| II | 14 (18.2%) | 5 (14.7%) | 4 (21.1%) | 5 (20.8%) | 9 (20.9%) | 0.489 |
| III | 7 (9.1%) | 2 (5.9%) | 0 | 5 (20.8%) | 5 (11.6%) | — |
b.p.m., beats per minute; ID, iron deficiency; LVEDV, left ventricular end‐diastolic volume; LVEDVi, left ventricular end‐diastolic volume index; LVEF, left ventricular ejection fraction; LVESV, left ventricular end‐systolic volume; LVESVi, left ventricular end‐systolic volume index; LV GLS, left ventricular global longitudinal strain; MR, mitral regurgitation; SD, standard deviation; TR, tricuspid regurgitation. Data are presented as mean ± SD or as n (%).
3.2. Iron metabolism of the study population group
Serum parameters of iron metabolism in our study population at baseline are summarized in Figure 1 . At enrolment, 43 patients (55.8%) were diagnosed with ID (31.2% with absolute ID and 24.7% with functional ID) and 34 patients (44.2%) with anaemia. Twenty‐five anaemic patients (73.5% of the anaemic subset) were also iron deficient (functional ID in 11 anaemic patients and absolute ID in 14 anaemic patients) (Figure 1 A). As depicted in Figure 1 B, mean corpuscular volume ranged from 74 to 108 fL with a mean of 89.7 ± 6.4 fL. In the majority of anaemic patients, we found a normocytic anaemia (n = 29, 87.9% of the anaemic subset), whereas macrocytic anaemia was found in one (3.0%) and microcytic anaemia in three patients (9.1%). Haemoglobin level ranged from 7.8 to 16.5 g/dL with a mean of 12.5 ± 2.0 g/dL. Serum ferritin levels ranged from 21 to 962 mg/L with a mean of 162.3 ± 138.3 mg/L. Transferrin saturation ranged from 3.9% to 58.4% with a mean of 21.0 ± 9.6%. Noteworthy, parameters of iron metabolism did not change in the course of the follow‐up period (data not shown).
Figure 1.
Iron metabolism of the study population group. (A) Percentage distribution of patients with no iron deficiency, functional iron deficiency, and absolute iron deficiency. Absolute iron deficiency is defined as serum ferritin < 100 μg/L and functional iron deficiency as ferritin 100–300 μg/L, if transferrin saturation is <20%. (B) Serum parameters of iron metabolism. ID, iron deficiency; MCH, mean corpuscular haemoglobin; MCV, mean corpuscular volume.
3.3. Response to cardiac resynchronization therapy
In our study cohort, echocardiographic CRT response with regard to LVEF improvement was observed in 64.9% of the overall study population, and improvement of LV GLS ≥ 20% occurred in 67.5% of the patients. Clinical improvement according to a change in NYHA functional class occurred in 62.3% of the patients during the follow‐up period (Supporting Information, Figure S1 ). Noteworthy, no significant differences in biventricular pacing rate were found in patients with ID compared with patients with no ID (97.8 ± 3.0 vs. 98.0 ± 3.0, P = 0.150). Echocardiographic parameters and QRS duration at baseline and at follow‐up (13.0 ± 3.3 months) are depicted in Supporting Information, Table S1 .
3.4. Predictors of non‐response to cardiac resynchronization therapy
In univariate analysis, ID, right bundle branch block (RBBB), and an LVEF at baseline ≥ 25% significantly correlated with echocardiographic CRT non‐response (Table 3). Moreover, ID, RBBB, an LVEF at baseline ≥ 25%, and a higher LV GLS were significant predictors of a lack of improvement in NYHA functional class on univariate analysis. After multivariate analysis, including co‐morbidities with a P‐value <0.05 and known predictors of CRT response, namely, male sex, coronary artery disease and a QRS width < 150 ms, ID, RBBB, and an LVEF ≥ 25% at baseline were identified as independent predictors of an echocardiographic CRT non‐response (Table 3). In addition, multivariate analysis demonstrated that ID and RBBB are significant predictors of non‐improvement of NYHA functional class (Table 3). Furthermore, we separately analysed the impact of both absolute and functional ID on CRT response (Table 3). Univariate analysis showed that absolute ID, RBBB, an LVEF at baseline ≥ 25%, and a higher LV GLS were associated with echocardiographic CRT non‐response and no improvement of NYHA functional class. After multivariate analysis, absolute ID, RBBB, and an LVEF ≥ 25% remained independent predictors of an echocardiographic CRT non‐response, whereas only absolute ID and RBBB were independent predictors of non‐improvement of NYHA functional class. In contrast, chronic renal failure (glomerular filtration rate < 60 mL/min) was no independent predictor of echocardiographic or clinical CRT response. LV lead positions in our study population had also no effect on reverse cardiac remodelling and clinical CRT response (data not shown).
Table 3.
Clinical Predictors of Non‐Response to Cardiac Resynchronization Therapy (A) Univariate and multivariate determinants of CRT non‐response comparing patients with iron deficiency with patients without iron deficiency. (B) Univariate and multivariate determinants of CRT non‐response comparing patients with functional iron deficiency and absolute iron deficiency with patients without iron deficiency
| A | ||||
|---|---|---|---|---|
| Univariate analysis | Binomial logistic regression analysis | |||
| Variable | P‐value | OR | 95% CI | P‐value |
| Relative change of LVEF < 20% | ||||
| Iron deficiency | 0.018 | 6.16 | 1.23–30.72 | 0.027 |
| RBBB | 0.013 | 7.91 | 1.13–55.11 | 0.037 |
| LVEF ≥ 25% at baseline | <0.001 | 8.92 | 1.65–48.33 | 0.011 |
| LV GLS at baseline | <0.001 | 1.41 | 0.93–2.14 | 0.103 |
| Male sex | 0.078 | 3.79 | 0.77–18.77 | 0.103 |
| ICM | 0.116 | 1.79 | 0.41–7.75 | 0.436 |
| QRS < 150 ms | 0.114 | 0.86 | 0.19–3.81 | 0.843 |
| Anaemia | 0.970 | 0.91 | 0.22–3.81 | 0.900 |
| Antiplatelet therapy | 0.554 | 0.45 | 0.10–2.05 | 0.304 |
| Relative change of LV Strain < 20% | ||||
| Iron deficiency | 0.014 | 4.55 | 0.94–21.96 | 0.041 |
| RBBB | <0.001 | 41.98 | 3.67–480.47 | 0.003 |
| LVEF ≥ 25% at baseline | <0.001 | 9.39 | 1.41–62.66 | 0.021 |
| LV GLS at baseline | 0.003 | 1.33 | 0.88–2.02 | 0.173 |
| Male sex | 0.142 | 2.72 | 0.54–13.72 | 0.227 |
| ICM | 0.248 | 0.73 | 0.16–3.22 | 0.675 |
| QRS < 150 ms | 0.013 | 2.35 | 0.55–10.01 | 0.250 |
| Anaemia | 0.99 | 1.05 | 0.23–4.76 | 0.952 |
| Antiplatelet therapy | 0.09 | 2.23 | 0.49–10.13 | 0.301 |
| No change of NYHA class | ||||
| Iron deficiency | 0.006 | 5.17 | 1.31–20.46 | 0.019 |
| RBBB | 0.024 | 6.05 | 1.09–33.56 | 0.039 |
| LVEF ≥ 25% at baseline | 0.023 | 2.65 | 0.70–10.01 | 0.152 |
| LV GLS at baseline | 0.007 | 1.33 | 0.95–1.86 | 0.102 |
| Male sex | 0.984 | 0.72 | 0.20–2.59 | 0.615 |
| ICM | 0.133 | 1.85 | 0.54–6.31 | 0.102 |
| QRS < 150 ms | 0.230 | 0.66 | 0.19–2.32 | 0.512 |
| Anaemia | 0.703 | 0.65 | 0.19–2.16 | 0.478 |
| Antiplatelet therapy | 0.145 | 1.27 | 0.36–4.46 | 0.709 |
| B | ||||
|---|---|---|---|---|
| Univariate analysis | Binomial logistic regression | |||
| Variable | P‐value | OR | 95% CI | P‐value |
| Relative change of LVEF < 20% | ||||
| Functional ID | 0.372 | 2.07 | 0.28–15.33 | 0.477 |
| Absolute ID | 0.003 | 14.48 | 2.03–103.59 | 0.008 |
| RBBB | 0.013 | 11.48 | 1.51–87.50 | 0.018 |
| LVEF ≥ 25% at baseline | <0.001 | 9.76 | 1.68–56.62 | 0.011 |
| LV GLS at baseline | <0.001 | 1.47 | 0.91–2.35 | 0.112 |
| Male sex | 0.078 | 3.15 | 0.62–16.06 | 0.167 |
| ICM | 0.116 | 1.85 | 0.38–9.02 | 0.448 |
| QRS < 150 ms | 0.114 | 1.18 | 0.23–6.22 | 0.843 |
| Anaemia | 0.970 | 1.05 | 0.23–4.87 | 0.955 |
| Antiplatelet therapy | 0.554 | 0.37 | 0.07–1.97 | 0.245 |
| Relative change of LV strain < 20% | ||||
| Functional ID | 0.053 | 3.43 | 0.47–25.01 | 0.225 |
| Absolute ID | 0.020 | 5.21 | 0.97–27.95 | 0.043 |
| RBBB | <0.001 | 44.91 | 3.88–519.37 | 0.002 |
| LVEF ≥ 25% at baseline | <0.001 | 9.34 | 1.40–62.32 | 0.021 |
| LV GLS at baseline | 0.003 | 1.33 | 0.88–2.02 | 0.179 |
| Male sex | 0.142 | 2.53 | 0.49–12.97 | 0.267 |
| ICM | 0.248 | 0.72 | 0.16–3.22 | 0.666 |
| QRS < 150 ms | 0.013 | 2.55 | 0.57–11.46 | 0.221 |
| Anaemia | 0.985 | 1.10 | 0.24–5.10 | 0.900 |
| Antiplatelet therapy | 0.094 | 2.24 | 0.49–10.29 | 0.300 |
| No change of NYHA class | ||||
| Functional ID | 0.095 | 3.12 | 0.62–15.79 | 0.170 |
| Absolute ID | 0.003 | 7.46 | 1.62–34.48 | 0.010 |
| RBBB | 0.024 | 7.23 | 1.25–41.71 | 0.027 |
| LVEF ≥ 25% at baseline | 0.023 | 2.49 | 0.65–9.56 | 0.185 |
| LV GLS at baseline | 0.007 | 1.31 | 0.92–1.87 | 0.133 |
| Male sex | 0.984 | 0.66 | 0.18–2.44 | 0.530 |
| ICM | 0.133 | 1.68 | 0.45–6.24 | 0.439 |
| QRS < 150 ms | 0.230 | 0.76 | 0.21–2.77 | 0.677 |
| Anaemia | 0.703 | 0.66 | 0.19–2.24 | 0.504 |
| Antiplatelet therapy | 0.145 | 1.18 | 0.32–4.32 | 0.806 |
CI, confidence interval; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; LV GLS, left ventricular global longitudinal strain; OR, odds ratio; RBBB, right bundle branch block.
3.5. Secondary endpoints
The secondary outcome, death from any cause during a mean follow‐up of 29.0 ± 8.4 months, occurred in 12 patients (15.6% of the study population) in the iron deficient group died, as compared with three patients (3.9%) in the group without ID (P = 0.045, Supporting Information, Figure S2 A). Analysis of functional and absolute ID as subgroups revealed a significant increase in all‐cause mortality in patients with absolute ID (P = 0.022) but not in patients with functional ID (Supporting Information, Figure S2 B). Overall, 25 patients (32.5% of the study population) were hospitalized for worsening of HF at least once during the follow‐up period (72.0% with ID vs. 28.0% without ID). In contrast to all‐cause mortality, the hospitalization rate for worsening of HF was not significantly different between patients with ID (functional and/or absolute) and normal iron status (Supporting Information, Figures S2 C and S2 D). The results of the univariate analysis and multivariate analysis are depicted in Supporting Information, Table S2 . Supporting Information, Figure S3 illustrates the cumulative all‐cause mortality of patients with ID and no ID (Supporting Information, Figure S3 A) and no ID vs. functional and absolute ID (Supporting Information, Figure S3 B). The cumulative freedom from HF admission with regard to the iron status is shown in Supporting Information, Figures S3 C and S3 D.
3.6. Short‐term and long‐term cardiac remodelling
Cardiac reverse remodelling at short‐term follow‐up (3.3 ± 1.9 months) and long‐term follow‐up (13.0 ± 3.2 months) after CRT implantation is depicted in Figure 2 . Relative LVEF and LV GLS improvement at short‐term follow‐up was similar in patients with and without ID. However, cardiac reverse remodelling in the period between short‐term follow‐up and long‐term follow‐up was more pronounced in patients with no ID compared with patients with absolute ID. Corresponding differences in LV GLS improvement were statistically significant (P = 0.026), whereas statistically significance was narrowly missed with regard to differences in LVEF improvement (P = 0.054).
Figure 2.
Time course of cardiac reverse remodelling. (A) Improvement in global left ventricular strain including baseline, short‐term follow‐up (3.3 ± 1.9 months) and long‐term follow‐up (13.0 ± 3.2 months) analysis. (B) Improvement in left ventricular ejection fraction including baseline, short‐term follow‐up (3.3 ± 1.9 months) and long‐term follow‐up (13.0 ± 3.2 months) analysis. FU, follow‐up; LVEF, left ventricular ejection fraction; LV GLS, left ventricular global longitudinal strain. The P‐values are from comparison between no iron deficiency and absolute iron deficiency at long‐term follow‐up.
3.7. Type of iron deficiency and cardiac resynchronization therapy response
Echocardiographic CRT response depending on iron status is shown in Supporting Information, Figure S4 . Allocating patients with ID according to the type of ID, linear‐by‐linear association test showed a significant linear‐by‐linear association between the type of ID and response to CRT. Thus, a linear‐by‐linear association was found between the type of ID and CRT response according to LVEF improvement (P = 0.004) and CRT response according to LV GLS improvement (P = 0.02). In addition, linear‐by‐linear analysis also revealed a strong association between clinical CRT response and type of ID (P = 0.003). The strength of the relationship (measured by Kendalis‐tau c values) was 0.35 for NYHA response, 0.34 for LVEF response, and 0.27 for LV GLS response.
3.8. ‘Super‐responder’ to cardiac resynchronization therapy
In this study, we defined super‐response to CRT as LVEF ≥ 50% at follow‐up. Using this definition, super‐response was observed in total in 10 patients (13.0%). In the super‐responder group, five patients (50%) had a normal iron status, four patients (40%) had a functional, and one patient (10%) had an absolute ID. However, due to the low number of super‐responders, a statistical analysis with regard to predictors of CRT super‐response is not useful.
3.9. Adverse cardiovascular events during patient follow‐up
During the follow‐up period of 13.0 ± 3.3 months, a total of 27 serious adverse events occurred (Table 4). These events were documented in 29.4% of the patients with normal serum parameters of iron metabolism, in 31.6% of the patients with functional ID and in 45.8% of the patients with absolute ID (no statistically significant difference). A total of 22 cardiovascular events, defined as HF hospitalization, and atrial or ventricular arrhythmias leading to hospitalization, occurred in seven patients (20.6%) with no ID, in six patients (31.6%) with functional ID, and in 11 patients (45.8%) with absolute ID. A total of five serious adverse events related to the device or implantation occurred. Atrial lead dislodgement occurred in total in two patients. Device pocket haematoma were observed in three patients and required clearing out the haematoma in one case.
Table 4.
Serious adverse events
| No ID (n = 34) | Functional ID (n = 19) | Absolute ID (n = 24) | P‐value functional ID vs. no ID | P‐value absolute ID vs. no ID | |
|---|---|---|---|---|---|
| All events | 10 (29.4%) | 6 (31.6%) | 11 (45.8%) | 0.971 | 0.236 |
| Cardiovascular events | |||||
| Heart failure hospitalization | 5 (50.0%) | 5 (83.3%) | 8 (72.7%) | 0.300 | 0.094 |
| Atrial arrhythmia | 0 | 1 (16.7%) | 0 | 0.177 | — |
| Ventricular arrhythmia | 2 (20.0%) | 0 | 1 (9.1%) | 0.281 | 0.771 |
| CRT system related | |||||
| ICD lead | 0 | 0 | 0 | — | — |
| LV lead | 0 | 0 | 0 | — | — |
| Atrial lead | 1 (10.0%) | 0 | 1 (9.1%) | 0.450 | 0.801 |
| Implantation related | |||||
| Haematoma | 2 (20.0%) | 0 | 1 (9.1%) | 0.281 | 0.771 |
| Pocket infection | 0 | 0 | 0 | — | — |
| Pneumothorax | 0 | 0 | 0 | — | — |
CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; ID, iron deficiency; LV, left ventricular. Adverse events after CRT implantation during a follow‐up of 13.0 ± 3.3 months. Data are presented as n (%).
4. Discussion
The main findings of this study are that (i) ID is a predictor of echocardiographic CRT non‐response, (ii) ID is a predictor of lack of improvement in NYHA functional class, and (iii) ID is associated with a significant increase in all‐cause mortality in CRT patients.
Iron deficiency (ID) is known to be an important co‐morbidity and strong and independent predictor of outcome in heart failure with reduced ejection fraction, with a prevalence ranging from 16% to 57% depending on the study population and criteria used.12, 33 The high prevalence of ID in our study cohort (55.8%) is comparable with previously published studies.12 According to previous studies, our data show that ID is often present even in the absence of anaemia.34
CRT is a proven and well‐established method that reduces morbidity and mortality in patients with symptomatic HF, reduced LVEF, and broadened QRS complex. However, up to one third of the CRT recipients do not benefit from biventricular stimulation, although the proportions of non‐responder vary depending on the definitions and criteria applied.9, 11 However, it must be considered that certain patients would deteriorate further in the absence of CRT.35 Remarkably, despite 20 years of CRT, a consensus definition of response and non‐response to CRT has not been reached. In our study population, CRT response included evaluation of reverse cardiac remodelling by echocardiography, change in NYHA functional class, and clinical outcome. At multivariate analysis, ID, RBBB, and an LVEF ≥ 25% were identified as independent predictors of echocardiographic non‐response to CRT. In addition, ID appeared as independent predictor of non‐improvement of NYHA functional class. This is important, as from a patient perspective, clinical improvement (NYHA functional class) is of higher relevance than echocardiographic improvement. Importantly, previous studies have shown that clinical response does not necessarily correlate with reverse cardiac remodelling.36 However, in our study population, the majority of echocardiographic CRT responders (82.0% and 82.7% in terms of LVEF and LV GLS improvement, respectively) also exhibited an improvement in NYHA functional class. Although functional ID was not an independent predictor of an echocardiographic CRT non‐response at multivariate logistic regression analysis, linear‐by‐linear association revealed a strong association between type of ID (functional and absolute ID) and response to CRT. Our study demonstrates that ID was related to an increased all‐cause mortality (3.82 times higher in patients with ID compared with patients without ID). However, in contrast to a previous study by Martens et al.24 we did not observe a significant difference in HF hospitalization associated with ID. Martens et al.24 and Bojarczuk et al.25 retrospectively evaluated CRT response only at 6 months of follow‐up. In contrast, we examined cardiac reverse remodelling at short‐term follow‐up (3.3 ± 1.9 months) and at long‐term follow‐up (13.0 ± 3.2 months) after CRT implantation. Interestingly, ID mainly affected the long‐term cardiac reverse remodelling, indicating an impact on factors other than restoring ventricular synchrony. The current concept of CRT is that it exerts its beneficial effects by improving ventricular synchrony. In addition, recent studies suggest that improving LV filling by shortening atrioventricular delay is an important mechanism through which CRT improves cardiac function.37 However, previous studies suggest that CRT also potently alters cellular energy metabolism in the mitochondria by specifically altering proteins that control the redox state and oxidative phosphorylation pathways within the mitochondria.38, 39
Data on a possible link between iron status and favourable cardiac reverse remodelling after CRT implantation are limited.24, 25 Following reasons for reduced reverse remodelling and clinical response in iron deficient CRT recipients in our study population are conceivable. First, ID might reflect a more advanced disease state with reduced ability to reverse remodelling. Second, ID itself might be responsible for the impaired reverse remodelling and clinical response to CRT. Our data do not prove a pathophysiological link of ID to CRT non‐response. However, we believe that the pathophysiological reason observed might be the role of iron as obligate component of diverse enzymes involved in cellular respiration, oxidative phosphorylation, citric acid cycle, and ROS production.19 Thus, especially metabolic active cells such as cardiomyocytes depend on iron for their function.40 Previously published animal data show that ID by itself impairs oxidative metabolism and cellular energetics that result in mitochondrial and LV dysfunction.41 In addition, Melenovsky et al.42 found in patient samples that reduced LV iron correlated with a lower activity of citric acid cycle enzymes, a reduced expression of ROS scavenging enzymes, and reduced mitochondrial oxygen consumption. Thus, myocardial ID in patients with HF may promote glucose rather than fatty acid utilization and may, in concert with impaired protection against ROS, contribute to diminished remodelling and clinical response to CRT.
Several randomized controlled trials reported an effect of intravenous iron administration on exercise capacity, NYHA class, and quality of life in patients with HF.20, 21, 22 In addition, a recent meta‐analysis by Anker et al.43 found that intravenous iron supplementation is associated with lower rates of mortality and cardiovascular hospitalizations. Thus, it is tempting to speculate that an intravenous iron replacement therapy could reduce the rate of CRT non‐responders.
5. Study limitations
The present study has several limitations. First, the study is a prospective observational study in a single centre with a relatively small number of patients. Thus, the incidence of HF hospitalization and death from any cause was low, which limits to analyse the secondary endpoints. Second, while our findings indicate that ID is a predictor of echocardiographic and clinical CRT non‐response, we did not analyse whether iron supplementation improves CRT response in non‐responder. Third, our study reports associations and correlations and does not prove a pathophysiological link of ID to CRT non‐response.
6. Conclusions
Our results show that the presence of ID predicts the lack of therapeutic efficacy of CRT therapy in both clinical terms (lack of NYHA improvement) and functional terms (lack of echocardiographic remodelling). We suggest that screening for ID at the time of CRT implantation is a relevant diagnostic step prior to CRT implantation. Further studies are necessary to evaluate whether iron supplementation improves CRT response in patients with ID.
Conflict of interest
None declared.
Funding
This research was financially supported by a Medtronic Research Grant.
Supporting information
Figure S1. Response to cardiac resynchronization therapy. CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; LV GLS, left ventricular global longitudinal strain; NYHA, New York Heart Association.
Figure S2. Outcome analysis. (A) All‐cause mortality of patients with no iron deficiency vs. patients with iron deficiency. (B) All‐cause mortality of patients without iron deficiency in comparison with patients with functional and absolute iron deficiency. (C) Hospitalization due to worsening of heart failure comparing patients without iron deficiency and with iron deficiency. (D) Hospitalization due to worsening of heart failure in patients without iron deficiency, functional iron deficiency and absolute iron deficiency patients. ID, iron deficiency. HR, hazard ratio; ID, iron deficiency.
Figure S3. Kaplan‐Meier curve for cumulative survival and hospitalization. (A) Kaplan‐Meier curves for death from any cause in patients with iron deficiency compared to patients with no iron deficiency and (B) patients with iron deficiency compared to patients with functional or absolute iron deficiency. (C) Kaplan‐Meier curves for hospitalization due to worsening of heart failure in patients with iron deficiency compared to patients with no iron deficiency and (D) patients with iron deficiency compared to patients with functional or absolute iron deficiency. ID, iron deficiency. The p values are from comparison between no iron deficiency and iron deficiency / absolute iron deficiency.
Figure S4. Response to cardiac resynchronization therapy depending on the iron status. ID, iron deficiency.
Table S1. Echocardiographic parameters at baseline and at follow‐up. Data are presented as mean ± SD or as n (%). LVEDV, left ventricular end‐diastolic volume; LVEDVi, left ventricular end‐diastolic volume index; LVESV, left ventricular end‐systolic volume; LVESVi, left ventricular end‐systolic volume index; LV GLS, left ventricular global longitudinal strain; MR, mitral regurgitation; TR, tricuspid regurgitation.
Table S2. Univariate and multivariate analysis for all‐cause mortality and hospitalization due to worsening of heart failure. CI, confidence interval; HR, hazard ratio; ID, iron deficiency.
Acknowledgement
The authors thank Christin Marx for her support in the study organization.
Lacour, P. , Dang, P. L. , Morris, D. A. , Parwani, A. S. , Doehner, W. , Schuessler, F. , Hohendanner, F. , Heinzel, F. R. , Stroux, A. , Tschoepe, C. , Haverkamp, W. , Boldt, L.‐H. , Pieske, B. , and Blaschke, F. (2020) The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE‐CRT Study. ESC Heart Failure, 7: 1072–1084. 10.1002/ehf2.12675.
References
- 1. Brignole M, Auricchio A, Baron‐Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Guidelines ESCCfP , Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, Kirchhof P, Blomstrom‐Lundqvist C, Badano LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the european society of cardiology (esc). Developed in collaboration with the european heart rhythm association (ehra). Eur Heart J 2013; 34: 2281–2329. [DOI] [PubMed] [Google Scholar]
- 2. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J, Evaluation MSGMIRC . Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845–1853. [DOI] [PubMed] [Google Scholar]
- 3. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D, Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ, Investigators M‐C . Effectiveness of cardiac resynchronization therapy by qrs morphology in the multicenter automatic defibrillator implantation trial‐cardiac resynchronization therapy (madit‐CRT). Circulation 2011; 123: 1061–1072. [DOI] [PubMed] [Google Scholar]
- 4. Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Kautzner J, Klempfner R, Kuniss M, Merkely B, Pfeffer MA, Quesada A, Viskin S, McNitt S, Polonsky B, Ghanem A, Solomon SD, Wilber D, Zareba W, Moss AJ. Survival with cardiac‐resynchronization therapy in mild heart failure. N Engl J Med 2014; 370: 1694–1701. [DOI] [PubMed] [Google Scholar]
- 5. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, Cardiac Resynchronization‐Heart Failure Study I . The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539–1549. [DOI] [PubMed] [Google Scholar]
- 6. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL, Resynchronization‐Defibrillation for Ambulatory Heart Failure Trial I . Cardiac‐resynchronization therapy for mild‐to‐moderate heart failure. N Engl J Med 2010; 363: 2385–2395. [DOI] [PubMed] [Google Scholar]
- 7. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS. An individual patient meta‐analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34: 3547–3556. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Auricchio A, Prinzen FW. Non‐responders to cardiac resynchronization therapy: the magnitude of the problem and the issues. Circ J 2011; 75: 521–527. [DOI] [PubMed] [Google Scholar]
- 9. Prinzen FW, Vernooy K, Auricchio A. Cardiac resynchronization therapy: state‐of‐the‐art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation 2013; 128: 2407–2418. [DOI] [PubMed] [Google Scholar]
- 10. Ypenburg C, Westenberg JJ, Bleeker GB, VAN de Veire N, Marsan NA, Henneman MM, van der Wall EE, Schalij MJ, Abraham TP, Barold SS, Bax JJ. Noninvasive imaging in cardiac resynchronization therapy—part 1: selection of patients. Pacing Clin Electrophysiol 2008; 31: 1475–1499. [DOI] [PubMed] [Google Scholar]
- 11. Mullens W, Grimm RA, Verga T, Dresing T, Starling RC, Wilkoff BL, Tang WH. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol 2009; 53: 765–773. [DOI] [PubMed] [Google Scholar]
- 12. Klip IT, Comin‐Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013; 165: 575–582 e573. [DOI] [PubMed] [Google Scholar]
- 13. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou‐Nana MI. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48: 2485–2489. [DOI] [PubMed] [Google Scholar]
- 14. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin‐Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD, Ponikowski P. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 2011; 17: 899–906. [DOI] [PubMed] [Google Scholar]
- 15. Enjuanes C, Klip IT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W, van Veldhuisen DJ, van der Meer P, Jankowska EA, Comin‐Colet J. Iron deficiency and health‐related quality of life in chronic heart failure: results from a multicenter european study. Int J Cardiol 2014; 174: 268–275. [DOI] [PubMed] [Google Scholar]
- 16. Rangel I, Goncalves A, de Sousa C, Leite S, Campelo M, Martins E, Amorim S, Moura B, Silva Cardoso J, Maciel MJ. Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients. Cardiology 2014; 128: 320–326. [DOI] [PubMed] [Google Scholar]
- 17. Yeo TJ, Yeo PS, Ching‐Chiew Wong R, Ong HY, Leong KT, Jaufeerally F, Sim D, Santhanakrishnan R, Lim SL, M Y Chan M, Chai P, Low AF, Ling LH, Ng TP, Richards AM, Lam CS. Iron deficiency in a multi‐ethnic asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail 2014; 16: 1125–1132. [DOI] [PubMed] [Google Scholar]
- 18. Nunez J, Comin‐Colet J, Minana G, Nunez E, Santas E, Mollar A, Valero E, Garcia‐Blas S, Cardells I, Bodi V, Chorro FJ, Sanchis J. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail 2016; 18: 798–802. [DOI] [PubMed] [Google Scholar]
- 19. Levi S, Rovida E. The role of iron in mitochondrial function. Biochim Biophys Acta 1790; 2009: 629–636. [DOI] [PubMed] [Google Scholar]
- 20. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole‐Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC‐HF: a randomized, controlled, observer‐blinded trial. J Am Coll Cardiol 2008; 51: 103–112. [DOI] [PubMed] [Google Scholar]
- 21. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole‐Wilson PA, Ponikowski P, Investigators F‐HT. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436–2448. [DOI] [PubMed] [Google Scholar]
- 22. Ponikowski P, van Veldhuisen DJ, Comin‐Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, Investigators C‐H. Beneficial effects of long‐term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 2015; 36: 657–668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen‐Solal A, Investigators E‐H . Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation; 136: 1374–1383. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Martens P, Verbrugge F, Nijst P, Dupont M, Tang WH, Mullens W. Impact of iron deficiency on response to and remodeling after cardiac resynchronization therapy. Am J Cardiol 2017; 119: 65–70. [DOI] [PubMed] [Google Scholar]
- 25. Bojarczuk J, Josiak K, Kasztura M, Kustrzycka‐Kratochwil D, Nowak K, Jagielski D, Banasiak W, Jankowska EA, Ponikowski P. Iron deficiency in heart failure: Impact on response to cardiac resynchronization therapy. Int J Cardiol 2016; 222: 133–134. [DOI] [PubMed] [Google Scholar]
- 26. Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, Frankel DS. Incidence and predictors of right ventricular pacing‐induced cardiomyopathy. Heart Rhythm 2014; 11: 1619–1625. [DOI] [PubMed] [Google Scholar]
- 27. Nutritional anaemias. Report of a who scientific group. World Health Organ Tech Rep Ser 1968; 405: 5–37. [PubMed] [Google Scholar]
- 28. Nakano H, Nagai T, Sundaram V, Nakai M, Nishimura K, Honda Y, Honda S, Iwakami N, Sugano Y, Asaumi Y, Aiba T, Noguchi T, Kusano K, Yokoyama H, Ogawa H, Yasuda S, Chikamori T, Anzai T, Na DEFi . Impact of iron deficiency on long‐term clinical outcomes of hospitalized patients with heart failure. Int J Cardiol 2018; 261: 114–118. [DOI] [PubMed] [Google Scholar]
- 29. Lang RM, Badano LP, Mor‐Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the european association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233–270. [DOI] [PubMed] [Google Scholar]
- 30. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, Pedri S, Ito Y, Abe Y, Metz S, Song JH, Hamilton J, Sengupta PP, Kolias TJ, d'Hooge J, Aurigemma GP, Thomas JD, Badano LP. Definitions for a common standard for 2d speckle tracking echocardiography: consensus document of the eacvi/ase/industry task force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 1–11. [DOI] [PubMed] [Google Scholar]
- 31. Mele D, Toselli T, Capasso F, Stabile G, Piacenti M, Piepoli M, Giatti S, Klersy C, Sallusti L, Ferrari R. Comparison of myocardial deformation and velocity dyssynchrony for identification of responders to cardiac resynchronization therapy. Eur J Heart Fail 2009; 11: 391–399. [DOI] [PubMed] [Google Scholar]
- 32. Killu AM, Mazo A, Grupper A, Madhavan M, Webster T, Brooke KL, Hodge DO, Asirvatham SJ, Friedman PA, Glikson M, Cha YM. Super‐response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy. Europace 2018; 20: 1303–1311. [DOI] [PubMed] [Google Scholar]
- 33. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34: 816–829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin‐Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872–1880. [DOI] [PubMed] [Google Scholar]
- 35. Kleijn SA, Aly MF, Knol DL, Terwee CB, Jansma EP, Abd El‐Hady YA, Kandil HI, Sorour KA, van Rossum AC, Kamp O. A meta‐analysis of left ventricular dyssynchrony assessment and prediction of response to cardiac resynchronization therapy by three‐dimensional echocardiography. Eur Heart J Cardiovasc Imaging 2012; 13: 763–775. [DOI] [PubMed] [Google Scholar]
- 36. Bleeker GB, Bax JJ, Fung JW, van der Wall EE, Zhang Q, Schalij MJ, Chan JY, Yu CM. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol 2006; 97: 260–263. [DOI] [PubMed] [Google Scholar]
- 37. Smiseth OA, Aalen JM. Mechanism of harm from left bundle branch block. Trends Cardiovasc Med 2019; 29: 335–342. [DOI] [PubMed] [Google Scholar]
- 38. Agnetti G, Kaludercic N, Kane LA, Elliott ST, Guo Y, Chakir K, Samantapudi D, Paolocci N, Tomaselli GF, Kass DA, Van Eyk JE. Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet 2010; 3: 78–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Wang SB, Foster DB, Rucker J, O'Rourke B, Kass DA, Van Eyk JE. Redox regulation of mitochondrial atp synthase: Implications for cardiac resynchronization therapy. Circ Res 2011; 109: 750–757. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Jankowska EA, Ponikowski P. Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin 2010; 6: 295–304. [DOI] [PubMed] [Google Scholar]
- 41. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005; 109: 277–286. [DOI] [PubMed] [Google Scholar]
- 42. Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail 2017; 19: 522–530. [DOI] [PubMed] [Google Scholar]
- 43. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin‐Colet J, Ruschitzka F, Luscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis. Eur J Heart Fail 2018; 20: 125–133. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Figure S1. Response to cardiac resynchronization therapy. CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; LV GLS, left ventricular global longitudinal strain; NYHA, New York Heart Association.
Figure S2. Outcome analysis. (A) All‐cause mortality of patients with no iron deficiency vs. patients with iron deficiency. (B) All‐cause mortality of patients without iron deficiency in comparison with patients with functional and absolute iron deficiency. (C) Hospitalization due to worsening of heart failure comparing patients without iron deficiency and with iron deficiency. (D) Hospitalization due to worsening of heart failure in patients without iron deficiency, functional iron deficiency and absolute iron deficiency patients. ID, iron deficiency. HR, hazard ratio; ID, iron deficiency.
Figure S3. Kaplan‐Meier curve for cumulative survival and hospitalization. (A) Kaplan‐Meier curves for death from any cause in patients with iron deficiency compared to patients with no iron deficiency and (B) patients with iron deficiency compared to patients with functional or absolute iron deficiency. (C) Kaplan‐Meier curves for hospitalization due to worsening of heart failure in patients with iron deficiency compared to patients with no iron deficiency and (D) patients with iron deficiency compared to patients with functional or absolute iron deficiency. ID, iron deficiency. The p values are from comparison between no iron deficiency and iron deficiency / absolute iron deficiency.
Figure S4. Response to cardiac resynchronization therapy depending on the iron status. ID, iron deficiency.
Table S1. Echocardiographic parameters at baseline and at follow‐up. Data are presented as mean ± SD or as n (%). LVEDV, left ventricular end‐diastolic volume; LVEDVi, left ventricular end‐diastolic volume index; LVESV, left ventricular end‐systolic volume; LVESVi, left ventricular end‐systolic volume index; LV GLS, left ventricular global longitudinal strain; MR, mitral regurgitation; TR, tricuspid regurgitation.
Table S2. Univariate and multivariate analysis for all‐cause mortality and hospitalization due to worsening of heart failure. CI, confidence interval; HR, hazard ratio; ID, iron deficiency.